Subscribe To
ENTX / Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates
ENTX News
By Zacks Investment Research
May 5, 2023
Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates
Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12. more_horizontal
By Zacks Investment Research
March 31, 2023
Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022. more_horizontal
By Zacks Investment Research
February 2, 2023
Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know
Entera Bio Ltd. (ENTX) closed at $0.95 in the latest trading session, marking no change from the prior day. more_horizontal
By Zacks Investment Research
January 25, 2023
Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know
In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.95, marking no change from the previous day. more_horizontal
By 24/7 Wall Street
November 23, 2022
Centillion Fund Inc. Ups Stake in Entera Bio (ENTX)
Fintel reports that Centillion Fund Inc. more_horizontal
By Benzinga
July 18, 2022
Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO
Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd (NASDAQ: ENTX) has designed the pivotal study for EB613 as an 18-month double-bl more_horizontal
By Seeking Alpha
May 18, 2022
Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q1 2022 Results - Earnings Call Transcript
Entera Bio Ltd. (NASDAQ:ENTX ) Q1 2022 Earnings Conference Call May 17, 2022 8:00 AM ET Company Participants Spiros Jamas - Chief Executive Officer Mi more_horizontal
By Seeking Alpha
March 8, 2022
Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2021 Results - Earnings Call Transcript
Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2021 Results - Earnings Call Transcript more_horizontal